An antibody framework binding interface for the cyclic meditopes C-QFDLSTRRLK-C (cQFD； SEQ ID NO:1) and C-QYNLSSRALK-C (cQYN； SEQ ID NO:2) and methods for their use are provided herein. In one embodiment, a binding interface is formed by a framework region, and not a complementarity determining region (CDR), of an antibody or functional fragment thereof. In another embodiment, a therapeutic human or humanized antibody has one or more human framework residues replaced with one or more corresponding murine residues such that a meditope having the sequence cQFD or cQYN stably binds the one or more human framework residues.
